The downstream application profile for PRRSV vaccine antigen concentrate is concentrated in injectable lyophilized, injectable suspension, injectable emulsion, frozen liquid bulk, and autogenous killed vaccine formats. Tablet and capsule finished dosage forms are not represented in this technical review because no current USDA-licensed or Ph. Eur.-monographed PRRSV vaccine uses oral solid dosing, and published release-specification data for viable PRRSV antigen in compressed tablet matrices are unavailable.

Sublimation Front Collapse in Freeze-Dried Live-Attenuated PRRSV Plugs

Lyophilized modified-live porcine reproductive and respiratory syndrome virus batches are filled as single-dose plugs in Type I glass vials with halobutyl rubber stoppers; the primary process conflict is maintaining product temperature below the collapse temperature of the stabilizer matrix during sublimation. The glass transition temperature of the maximally freeze-concentrated matrix in sucrose-gelatin systems is typically between -35°C and -28°C, and the collapse temperature determined by freeze-drying microscopy is usually 2–5°C above T_g'. Production-scale lyophilizers with shelf temperature uniformity of ±1°C and capacitance manometry-controlled chamber pressure are used; product thermocouples may read 2–5°C colder than the actual dried cake during primary drying due to vial-edge heating patterns, which is why batch endpoints are confirmed by comparing Pirani gauge and capacitance manometer readings rather than relying on product thermocouples alone. Standard stabilizer matrices published for enveloped mammalian veterinary viral vaccines contain sucrose at 2–8% w/w, trehalose at 1–5% w/w, hydrolyzed gelatin at 0.5–1.5% w/w, and potassium phosphate buffer at 10–50 mM; the clarified virus harvest is incorporated at 45–65% w/w of the final bulk, and final fill titer is not less than 10^4.0 TCID50 per dose based on USDA-licensed modified-live label minimums. Compliance is anchored to 9 CFR Part 113 safety and sterility requirements, USP <71> sterility, USP <921> residual moisture with a batch acceptance limit of ≤3.0% water content, EU GMP Annex 2 for biological active substances, and ISO 14644-1 cleanroom classification for aseptic filling zones. The downstream manufacturing sequence includes MARC-145 or MA-104 cell expansion in stirred-tank bioreactors, virus inoculation at 0.01–0.1 TCID50/cell, harvest at 48–72 h post-infection, depth filtration through 1.2 µm + 0.45 µm capsule filters, diafiltration against the stabilizer buffer to remove serum and host-cell proteins, aseptic filling into 2 mL/10 mL vials, and lyophilization with a freeze step at -45°C, primary drying at -20°C to -10°C and chamber pressure of 50–150 µbar, secondary drying at 25–35°C for 6–12 h, and vacuum stoppering under dry nitrogen. Terminal finished product type is a lyophilized plug for reconstitution with sterile diluent and intramuscular administration to growing pigs and breeding animals.

Aqueous inactivated PRRSV suspensions require a non-replicating antigen with alum adsorption rather than a modified-live construct, and the formulation addition ratio is typically 70–80% v/v clarified inactivated virus harvest with 20–30% v/v stabilizer and adjuvant slurry, including aluminum hydroxide at 0.5–2.0% w/v Al equivalent and residual formalin neutralized to below 0.05% v/v. Inactivation is performed with binary ethylenimine at 2–5 mM for 24–36 h at 37°C, followed by neutralization with sodium thiosulfate at a 1:1 molar ratio to BEI; alternative formalin inactivation at 0.05–0.2% v/v is used only when downstream potency testing confirms retention of ORF5 and ORF6 conformational epitopes. Compliance is maintained under 21 CFR Part 211 current good manufacturing practice, USP <71> sterility, USP <85> bacterial endotoxin with a product-specific limit established during validation, and EU GMP Annex 2 for biological active substances. Aluminum hydroxide adsorption is pH-sensitive: below pH 6.5, the positively charged adjuvant surface binds less of the negatively charged envelope glycoprotein, and pH drift greater than 0.5 units during inactivation must be corrected before adsorption. The downstream process includes PRRSV propagation in MARC-145 cells, harvest clarification through 1.2 µm + 0.45 µm filters, BEI inactivation in stirred jacketed stainless steel vessels, diafiltration to remove inactivation by-products, adsorption onto aluminum hydroxide at 200–500 rpm and pH 6.5–7.5, and aseptic filling into 2 mL intramuscular doses. Terminal finished product type is an aqueous aluminum hydroxide-adjuvanted killed PRRSV suspension for intramuscular injection of sows and replacement gilts.

Does Rotor-Stator Emulsification at D50 Below 3 µm Destroy the Enveloped PRRSV Antigen?

High-shear mixing of killed PRRSV antigen into water-in-oil emulsion is constrained by the relationship between droplet size, shear rate, and antigen degradation; rotor-stator equipment with 3000–6000 rpm tip speeds of 8–15 m/s is used, and batch temperature is maintained below 30°C to avoid emulsion inversion or antigen denaturation. Rotor-stator mixers can generate local temperature rises of 5–15°C above jacket setpoint if recirculation is inadequate; therefore jacketed vessels with temperature probes in the recirculation loop rather than only in the vessel wall are preferred. The formulation addition ratio is oil phase at 50–70% w/w mineral oil, antigen aqueous phase at 30–45% w/w, sorbitan monooleate at 2–6% w/w, and polysorbate 80 at 0.5–2% w/w; final emulsion viscosity is typically 40–200 mPa·s at 25°C, and droplet D50 is controlled to 1–5 µm because larger droplets accelerate creaming and smaller droplets may expose the antigen to excessive interfacial shear. Compliance is established through ISO 13320:2020 laser diffraction for droplet size analysis, ISO 22412:2017 for dynamic light scattering in candidate nano-emulsions, USP <71> sterility, USP <85> endotoxin, and 21 CFR Part 211 cGMP; stability is evaluated under 4°C and 25°C accelerated conditions for phase separation and mean droplet size drift. The downstream process includes sterilization of the oil phase at 121°C for 30 min, cooling to 25–30°C, preparation of the aqueous antigen phase at 4–8°C, slow addition of aqueous phase to oil under high shear, and homogenization until a stable primary emulsion forms, followed by low-shear mixing for 15–30 min to reduce foam. Terminal finished product type is a water-in-oil adjuvanted killed PRRSV emulsion for intramuscular injection in sows and gilts, typically supplied as a 2 mL or 5 mL dose.

When the final formulation site is not the virus propagation site, frozen liquid PRRSV antigen concentrate used as a starting material for downstream killed vaccine manufacture requires cold chain discipline that is often underestimated in toll manufacturing. The addition ratio of cryoprotectant to clarified virus concentrate is 10–20% w/w glycerol or 5–10% w/w dimethyl sulfoxide, with phosphate-buffered saline making up the remaining diluent; published data for PRRSV-specific DMSO cryopreservation is limited, and glycerol-containing formulations are preferred for enveloped viral bulks because membrane fusion-competent titers are retained during slow freezing. Repeated freeze-thaw cycles reduce infectivity by 0.5–1.0 log per cycle in some enveloped virus stocks; therefore single-use aliquots are filled to avoid multiple thaw events. Compliance is governed by USDA 9 CFR 102.5 for autogenous biological products, USP <71> sterility, USP <85> endotoxin, and USP <659> for packaging and storage integrity, with release testing that includes absence of mycoplasma and extraneous porcine viruses. The downstream process includes PRRSV isolation from affected herd serum or lung tissue, propagation on MARC-145 cells, harvest at 48–72 h, clarification through 0.65 µm + 0.45 µm filters, concentration by tangential flow filtration with 100–300 kDa membranes, diafiltration into stabilizer buffer, addition of cryoprotectant under chilled mixing, and filling into sterile cryovials or single-use bags before controlled-rate freezing to below -60°C. Terminal finished product type is a frozen antigen concentrate that is later thawed, inactivated, and formulated into an injectable autogenous killed vaccine for the originating herd or production site.

When a Production System Requires a Homologous Autogenous Killed PRRSV Formulation

Autogenous killed PRRSV vaccines are formulated when a production system isolates a farm-specific variant and a licensed commercial vaccine does not match the circulating ORF5 lineage; the formulation addition ratio is dictated by the amount of in-process antigen concentrate rather than a fixed commercial matrix, typically 20–50% v/v antigen concentrate, 5–15% v/v aluminum hydroxide gel or 10–20% v/v oil adjuvant, and the remainder sterile diluent or buffer at pH 7.0–7.4. Compliance is defined by USDA 9 CFR 102.5 and relevant state veterinary biologics regulations, with sterility per USP <71>, endotoxin per USP <85>, and inactivation verification through two blind passages on MARC-145 cells to confirm absence of residual live virus. The downstream process begins with whole blood, nasal swab, or lung tissue from the affected pig population, followed by RT-PCR confirmation of PRRSV, virus isolation on MARC-145 cells, seed stock preparation, scale-up in roller bottles or small bioreactors, BEI inactivation at 2–5 mM for 24–36 h at 37°C, neutralization, diafiltration, sterile filtration where possible, adjuvant blending, and filling into 2 mL or 5 mL vials. Terminal finished product type is an injectable autogenous killed PRRSV vaccine restricted to the originating herd under veterinary prescription.